Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
fda-logo

FDA public hearing: Microbiology Medical Devices Panel for Sepsis

FDA public hearing: Microbiology Medical Devices Panel for Sepsis November 10, 2016 Washington, DC. This was an open hearing on how recent regulatory changes affect the application of host response sepsis diagnostics for the clinical management of Antibiotics. Attended by the FDA Molecular Diagnostics Advisory Board IXP Staff in Attendance:...
ESICM

European Society for Intensive Care Medicine

European Society for Intensive Care Medicine October 1-5, 2016 Milan, Italy. Dr Mahdad Noursadeghi, of University College London presented preliminary results in a validation trial of an Immunexpress developed signature for the diagnosis of bacterial infection in patients presenting to ER, and for a second signature in the same validation...
Immunexpress.com

SeptiCyte™ LAB Differentiates Sepsis from Infection-Negative Systemic Inflammation in Critically Ill Children

Results of a Pilot Study of SeptiCyte™ LAB in the Pediatric Setting Published in Critical Care Medicine SEATTLE, Sept. 22, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and patients at risk of sepsis, announced today the publication, in Critical Care Medicine,...
RSF-Forum-2016-Banner

Third National Forum on Sepsis

National Sepsis Forum 2016 September 12, 2016 New York, NY. CEO Roz Brandon invited to attend the 3rd National Sepsis Forum 2016 held by the Rory Staunton Foundation, "New Ideas on Sepsis.” New York State has led the country in its holistic approach to sepsis prevention, treatment and awareness. The Third National Forum will showcase...
InnovateLogoTagline2-500x383

Taking Down The Hospital’s Biggest Killer

By testing white blood cells and monitoring “expression biomarkers,” SeptiCyte – a proprietary technology of Immunexpress – aims to provide faster and more accurate diagnosis of sepsis. By Gregory Zeller.
Immunexpress.com

SeptiCyte™ LAB Outperforms Other Parameters for Distinguishing Sepsis in Data Presented at the American Thoracic Society International Conference

SEATTLE, May 18, 2016 -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by...
ATS 2

American Thoracic Society (ATS) 2016 International Conference

American Thoracic Society 2016 May 13-18, 2016 San Francisco, CA. Bert Lopansri of Intermountain Health Care presented data on the usage of SeptiCyte™ technology to better inform management and reduce risk for patients in the early stages of ICU admission when other diagnostics available at this time either lack accuracy...
Immunexpress.com

Immunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ LAB

SEATTLE, May 11, 2016 -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the...
Immunexpress.com

Immunexpress and Academic Medical Center to Collaborate on Development of Sepsis-Related Biomarker Panels

SEATTLE, April 19, 2016 -- Immunexpress Inc. today announced an exclusive collaboration with the Academic Medical Center (AMC) at the University of Amsterdam to characterize and clinically evaluate sepsis and sepsis-related biomarker signatures of the host response. This four-year collaboration with AMC's Prof. Dr. Tom van der Poll and his team...
ICICEM small

Sepsis: 2026

A plenary lecture that took a journey through how we may treat sepsis in 10 years was featured with Steven Opal (Rhode Island Hospital, Providence, RI, USA) stepping up to speak about the expectations, hopes and remaining challenges in the field.
ICICEM small

36th International Symposium on Intensive Care and Emergency Medicine

36th International Symposium on Intensive Care and Emergency Medicine March 15-18, 2016 Brussels, Belgium. Russ Miller, of Intermountain Healthcare presented data on the market need for accurate sepsis diagnostics using results from the IXP VENUS trial showing that expert physicians agree on a diagnosis of sepsis in between 60 to...
Immunexpress.com

Immunexpress Presents on the Need for an Objective Diagnostic Tool for Systemic Inflammation at the International Symposium on Intensive Care and Emergency Medicine

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the presentation of data from the VENUS trial by Dr. Bert Lopansri of Intermountain Medical Center at the 36th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium. The presentation describes the...

If you are a member of the media, please contact:

Scott Stachowiak
Russo Partners
(646) 942-5630
scott.stachowiak@russopartnersllc.com